类风湿关节炎缓解期治疗变更与影像学进展的生物标志物:5年随访研究
33.3%患者因治疗变更退出缓解,其独立相关因素包括BMI、未使用生物DMARD、第一年MRI侵蚀进展及钙卫蛋白水平;10%患者出现影像学进展,与第一年MRI侵蚀和骨髓水肿进展相关。
要点
- 缓解期RA中约三分之一患者5年内需治疗变更,与BMI、未用生物DMARD、MRI侵蚀进展和钙卫蛋白相关。
- 影像学进展不常见(10%),但第一年MRI侵蚀和骨髓水肿进展者风险更高。
- 滑膜活检中肥大细胞密度与临床复发独立相关。
核心结论
- 缓解期RA患者5年内约三分之一失去临床缓解并变更治疗,独立相关因素为BMI、未使用生物DMARD、第一年MRI侵蚀评分进展和血清钙卫蛋白水平。
- 显著影像学进展不常见,但第一年MRI侵蚀和骨髓水肿进展与后续影像学进展相关。
主要发现
- 20例(33.3%)变更治疗,与BMI(OR 1.3,95%CI 1-1.7)、未使用生物DMARD(OR 24.7,95%CI 2.3-257.2)、第一年MRI侵蚀进展(OR 1.2,95%CI 1-1.3)和钙卫蛋白血清水平(OR 2.8,95%CI 1-8.2)相关。
- 6例(10%)出现影像学进展,其第一年MRI侵蚀进展(P=0.03)和骨髓水肿进展(P=0.04)更高。
- 23例行滑膜活检的患者中,肥大细胞密度与临床复发独立相关。
关键数值与推荐
- 影像学进展定义为5年时改良Sharp van der Heijde评分变化>10.47(最小可检测变化)。
- 缓解定义为DAS28-ESR<2.6。
临床怎么用
- 对缓解期RA患者,可关注BMI、生物DMARD使用状态、第一年MRI侵蚀进展和钙卫蛋白水平以识别治疗变更风险。
- 第一年MRI侵蚀和骨髓水肿进展可能提示后续影像学进展风险,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify biomarkers of treatment change and radiographic progression in patients with RA under remission. PATIENTS AND METHODS: RA patients in remission (DAS28-ESR <2.6) were selected and followed up for 5 years. An MRI of the dominant hand and an US assessment of knees/hands and serum levels of inflammation/angiogenesis biomarkers were performed at baseline and at 12th month. Synovial biopsies were obtained in patients with Power Doppler signal. Conventional radiographies of hands/feet were taken at baseline and after 5 years. Radiographic progression was defined as the change in the modified Sharp van der Heijde Score at 5 years >10.47 (small detectable change). RESULTS: Sixty patients were included, 81.6% were ACPA+ and 45% were taking biological DMARDs. At baseline, 66.6% had Power Doppler signal. After 5 years, 73.3% of patients remained in remission. Change of therapy was performed in 20 patients (33.3%) and was associated with BMI [odds ratio (OR) 1.3, 95% CI: 1, 1.7], lack of biological DMARD therapy (OR 24.7, 95% CI: 2.3, 257.2), first-year progression of MRI erosions (OR 1.2, 95% CI: 1, 1.3) and calprotectin serum levels (OR 2.8, 95% CI: 1, 8.2). Radiographic progression occurred in six (10%) patients. These patients had higher first-year progression of MRI erosions (P = 0.03) and bone oedema (P = 0.04). Among 23 patients undergoing synovial biopsy, mast cell density was independently associated with clinical flares. CONCLUSIONS: One-third of RA patients lost clinical remission and changed therapy throughout the 5 years of follow-up, which was independently associated with BMI, lack of biological DMARDs therapy and first-year progression of MRI erosion score and calprotectin serum levels. Significant radiographic progression was uncommon.
引用
- Ramírez J, Cuervo A, Celis R, et al. Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. Rheumatology (Oxford). 2021. PMID: 32653929. doi:10.1093/rheumatology/keaa258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。